Alimera Sciences, Inc. (NASDAQ:ALIM) major shareholder Armistice Capital Master Fund bought 20,000 shares of Alimera Sciences stock in a transaction that occurred on Tuesday, February 6th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $22,800.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Alimera Sciences, Inc. (NASDAQ ALIM) remained flat at $$1.09 during trading on Friday. The stock had a trading volume of 256,305 shares, compared to its average volume of 161,069. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. The firm has a market capitalization of $75.37, a PE ratio of -3.52 and a beta of 1.79. Alimera Sciences, Inc. has a 12-month low of $1.03 and a 12-month high of $1.72.
Several research firms recently commented on ALIM. ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a research report on Friday, October 27th. Finally, Cowen reissued a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $3.38.
COPYRIGHT VIOLATION WARNING: “Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Acquires 20,000 Shares” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/02/10/alimera-sciences-inc-alim-major-shareholder-armistice-capital-master-fund-acquires-20000-shares.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.